biostudies-literatureUnknown4Irvine MABiostime Institute for Nutrition and Care – GenevaSwisse WellnessVerdure SciencesBayerCranberry InstituteUniversity of IllinoisAbbott NutritionDiagnostic Services Manitoba<h4>Introduction</h4>The Cognitive Ageing, Nutrition and Neurogenesis trial hypothesizes that a combined intervention with long-chain n-3 polyunsaturated fatty acids (n-3) and cocoa flavan-3-ols (FLAV) will mitigate the cognitive decline anticipated to naturally occur over 1 year in older adults.<h4>Methods</h4>In a double-blinded, placebo-controlled parallel design, 259 individuals with mild cognitive impairment or subjective memory impairment were randomized to a control or n-3 FLAV group (1.5 g docosahexaenoic acid + eicosapentaenoic acid and 500 mg n-3 FLAV daily) for 12 months. Cognition was measured at 0, 3, and 12 months. The primary end-point is hippocampus-sensitive cognitive function (e.g., number of false-positives on the Picture Recognition Task of the Cognitive Drug Research tAlzheimer's & dementia (New York, N. Y.)591-601https://www.ebi.ac.uk/biostudies/studies/S-EPMC6222033biostudies-literatureThe Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progress.PMC6222033Sutton BPWesnes KADas TVauzour DCohen NJDemichele SJIrvine MALarsen RMinihane AMWhite DCassidy APipingas AScholey APotter JFGillings RJohnson GKing RfalseThe Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progress.<h4>Introduction</h4>The Cognitive Ageing, Nutrition and Neurogenesis trial hypothesizes that a combined intervention with long-chain n-3 polyunsaturated fatty acids (n-3) and cocoa flavan-3-ols (FLAV) will mitigate the cognitive decline anticipated to naturally occur over 1 year in older adults.<h4>Methods</h4>In a double-blinded, placebo-controlled parallel design, 259 individuals with mild cognitive impairment or subjective memory impairment were randomized to a control or n-3 FLAV group (1.5 g docosahexaenoic acid + eicosapentaenoic acid and 500 mg n-3 FLAV daily) for 12 months. Cognition was measured at 0, 3, and 12 months. The primary end-point is hippocampus-sensitive cognitive function (e.g., number of false-positives on the Picture Recognition Task of the Cognitive Drug Research t2018-01-01T00:00:00Z20182026-05-04T23:20:12.276Z2019-03-26T22:35:35ZS-EPMC62220333042606710.1016/j.trci.2018.08.001